| 摘要: |
| 目的 比较分析瑞舒伐他汀和阿托伐他汀治疗冠心病的临床效果。 方法 选取该院2014年6月—2016年9月心内科收治的160例冠心病患者,随机分为观察组和对照组,每组80例,观察组患者给予瑞舒伐他汀进行治疗,对照组同一时刻给予同等剂量的阿托伐他汀进行治疗,连续治疗1个月后,观察两组患者治疗前后的血脂水平和不良反应发生率。 结果 两组患者治疗后TC、TG 、LDL-C水平均降低,HDL-C水平均升高。观察组治疗后TC(4.01±0.50)mmol/L、TG(1.44±0.49)mmol/L 、LDL-C(1.95±0.32)mmol/L和HDL-C(1.79±0.14)mmol/L水平优于对照组[(4.78±0.49)mmol/L、(1.69±0.41)mmol/L、(2.35±0.39)mmol/L、(1.15±0.11)mmol/L](P<0.05)；治疗后观察组患者不良反应发生率(20.0%)显著低于对照组患者(35.0%),比较差异有统计学意义(P<0.05)。 结论 对于冠心病患者来说,相同剂量的瑞舒伐他汀的调脂效果优于阿托伐他汀,且不良反应发生率低于阿托伐他汀。 |
| 关键词: 瑞舒伐他汀 阿托伐他汀 冠心病 效果 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Comparison of rosuvastatin and atorvastatin in the treatment of coronary heart disease |
|
胡建国
|
|
河南省巩义市人民医院 河南省巩义市人民医院 Gongyi Municipal People's Hospital of Henan Province
|
| Abstract: |
| Objective To compare and analyze the clinical effect of rosuvastatin and atorvastatin in the treatment of coronary heart disease. Methods 160 cases of patients with coronary heart disease in our hospital from June 2014 to September 2016 were selected from Department of Cardiology, were randomly divided into observation group and control group, each with 80 cases in each group, the observation group were given rosuvastatin treatment, control group at the same time given the same dose of atorvastatin treatment, continuous 1 months after treatment were observed before and after two groups of patients changes in blood lipids and the incidence of adverse reactions. Results after treatment, the levels of TC, TG and LDL-C decreased, and the level of HDL-C increased in the two groups. The observation group after treatment, TC (4.01 + 0.50) mmol/L, TG (1.44 + 0.49) mmol/L, LDL-C (1.95 + 0.32) mmol/L and HDL-C (1.79 + 0.14) mmol/L levels than the control group [(4.78 + 0.49), mmol/L (1.69 + 0.41), mmol/L (2.35 + 0.39) mmol/L, (1.15. 0.11) mmol/L], there was significant difference between two groups (P<0.05); after treatment, the observation group the incidence of adverse reactions was 20%, patients in the control group the incidence of adverse reaction was 35%, there was significant difference between two groups (P<0.05). Conclusion for patients with coronary heart disease, the same dose of rosuvastatin lipid-lowering effect is better than atorvastatin, and the incidence of adverse reactions is lower than atorvastatin. |
| Key words: Rosuvastatin atorvastatin coronary heart disease effect |
